Home > Protocol Summaries: Compounds > rosiglitazone/metformin

Protocol Summaries: rosiglitazone/metformin

GSK Study ID	Phase	Title	Status
101765	Phase 4	Comparison of the action of the rosiglitazone-metformin fixed-dose combination and of a metformin-sulfonylurea free combination on the b-cell function in type 2 diabetic patients not controlled with metformin alone.	Completed
104988	Phase 4	Comparison of the effects of rosiglitazone and glimepiride, both given in combination with metformin, on 24-hour glycemia in type 2 diabetes patients not controlled with metformin alone. A 3-month multicentre, randomized, parallel-group, open-label study.	Completed
105709	n\a	An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of Avandamet® administered in Korean Diabetic patients according to the prescribing information	Completed
113030	phase 4	Evaluation of the duration of oral combination therapy in Type 2 diabetes, prior to the initiation of insulin in the UK	Completed
114040	phase 1	Assessment of relative bioavailability of Avandamet 4 mg + 1000 mg (GSK) in the form of film coated tablets versus Avandamet 2 mg + 500 mg (GSK) in the form of film coated tablets, in healthy volunteers after feeding standardized, using Liquid Chromatography.	Completed
712753/004	phase 3	An open-label trial to evaluate the safety and efficacy of fixed dose rosiglitazone/metformin combination therapy in poorly-controlled subjects with type 2 diabetes mellitus	Completed
712753/007	phase 3	A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects	Completed
712753/008	phase 4	AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, multicenter study to compare the efficacy and tolerability of AVANDAMET to metformin monotherapy in subjects with Type 2 Diabetes Mellitus who are not achieving glycemic control on submaximal metformin.	Completed
712753/009	phase 3	A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET* (8.0 mg / 2.0 g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy	Completed
AVM100264	Phase 3	A randomised, multi-centre, phase IV, double-blind, parallel group study comparing the effects of 52 weeks administration of AVANDAMET and metformin plus sulphonylurea on change in HbA1c from baseline in overweight type 2 diabetics poorly controlled on metformin.	Completed
AVT105913	phase 4	A randomized, parallel group, double-blind, multi-center study comparing the efficacy and safety of AVANDAMET and metformin after 80 weeks of treatment.	Completed